

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: **Maurer et al.**

Application Serial No.: **Filed Concurrently Herewith**

Group Art Unit: **Not Assigned**

Filed: **Filed Concurrently Herewith**

Examiner: **Not Assigned**

For: ***Fenretinide Composition with Increased Bioavailability and Ease of Administration***

Date: January 29, 2004

MAIL STOP PATENT APPLICATION

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Sir:

Attached is a list of documents on Form PTO-1449, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the waiver by the U.S. Patent and Trademark Office of requirements under 37 C.F.R. § 1.98(a)(2)(i) for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC § 371 after June 30, 2003.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP. No fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,


Kenneth D. Sibley


Registration No. 31,665

Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428
Raleigh, North Carolina 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401
Customer No. 20792

CERTIFICATE OF EXPRESS MAILING

"Express Mail" mailing label number: EV381447871 US
Date of Deposit: January 29, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mailstop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450


Lyndsey D. Hall, CP
Certified Paralegal

| | | | | | |
|---|---|----|---|--------------------------|-----------------------------|
| Substitute form 1449A/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | Filed Concurrently Herewith |
| | | | | Filing Date | January 29, 2004 |
| | | | | First Named Inventor | Maurer et al. |
| | | | | Group Art Unit | Not Yet Assigned |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 1 | of | 1 | Attorney Docket Number | 9022-41 |

| U.S. PATENTS AND PATENT PUBLICATIONS | | | | | |
|--------------------------------------|----------|----------------------|-------------------------|---|---|
| Examiner Initials* | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
| | | Number | Kind Code (if known) | | |
| | 1. | 4,874,795 | | David W. Yesair | 10-17-1989 |
| | 2. | 5,891,466 | | David W. Yesair | 04-06-1999 |
| | 3. | 5,972,911 | | David W. Yesair | 10-26-1999 |
| | 4. | 6,368,831 | | Maurer et al. | 04-09-2002 |
| | | | | | |
| | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|-------------|-------------------------|--------------|-------------------------|--|--|---|
| Examiner Initials* | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | T |
| | | Office | Number | Kind Code (if known) | | | |
| | 5. | PCT | WO 02/058689 | | Childrens Hospital Los Angeles | 08-01-2002 | |
| | 6. | PCT | WO 03/031593 | A2 | Biomolecular Products, Inc. | 04-17-2003 | |
| | 7. | PCT | WO 03/031593 | A3 | Biomolecular Products, Inc. | 04-17-2003 | |
| | | | | | | | |
| | | | | | | | |

| OTHER NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------------|----------|--|---|--|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T | |
| | 8. | REYNOLDS ET AL., <i>Retinoic-Acid-Resistant Neuroblastoma Cell Lines Show Altered MYC Regulation and High Sensitivity to Fenretinide</i> , <i>Medical and Pediatric Oncology</i> , 35 :597-602 (2000) | | |
| | 9. | LEPAGE ET AL., <i>Effect of an Organized Lipid Matrix on Lipid Absorption and Clinical Outcomes in Patients with Cystic Fibrosis</i> , <i>J. Pediatr.</i> , 141 :178-85 (2002) | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.